In 2023, the US state of Connecticut plans to launch psilocybin mushroom and ecstasy treatment programs, which will be funded from the regional budget.
The U.S. Food and Drug Administration (FDA) has developed an Expanded Drug Access Program to enable patients to access drugs that have been shown to be safe in Phase 1 clinical trials but not yet proven effective in human trials. The list of these medicines, in particular, includes psilocybin and MDMA. Therefore, in Connecticut, therapies using these substances will be carried out under the FDA program.
First, the state is going to set up a psychedelic-euphoretic treatment trial project for 100 veterans suffering from depression or post-traumatic stress disorder. Psilocybin and MDMA will be given to combatants who have not been helped by traditional methods of dealing with these ailments. During the pilot program, specialists will collect data on the consequences of taking psychoactive substances in order to evaluate their effectiveness and develop effective treatment protocols.
The government will fund the project until the US Drug Enforcement Division recognizes that MDMA and psilocybin have medicinal properties, thus removing these substances from Schedule I narcotic drugs, which includes substances that have no medical value. After that, the authorities will issue grants to private organizations to provide services in the field of psychedelic and euphoric therapy.
In May 2022, Connecticut Governor Ned Lamont signed a decree creating an ecosystem in the state for psychedelic and ecstasy treatment. An advisory council has been formed in the region that will be responsible for the infrastructure needed for safe and affordable substance treatment. For example, for this it will be necessary to train a sufficient number of qualified doctors.
Walter Dunn, assistant professor of psychiatry at the University of California, Los Angeles, believes that the success of the pilot program will push the governments of Connecticut and other American states to legalize medical psilocybin. The information obtained will allow officials to strike a balance between the safety, efficacy and availability of the psychedelic. Psilocybin is currently legal for medicinal use in only one region of the United States, Oregon.